Pasithea Therapeutics is a clinical-stage biotechnology company developing treatments for RASopathies, MAPK pathway-driven tumors, and central nervous system disorders. Its lead product, PAS-004, is a next-generation macrocyclic MEK 1/2 inhibitor designed to overcome limitations of existing therapies, with primary development in neurofibromatosis type 1 and applications in various cancer types and neurological conditions, while an earlier-stage program targets complement component 4A for schizophrenia. The company has no current product revenues and finances operations through capital raises, with commercialization strategy centered on direct pharmaceutical sales, licensing partnerships, and third-party payor reimbursement once regulatory approvals are obtained.